Saroglitazar Magnesium is being evaluated for its efficacy in treating Non-alcoholic Steatohepatitis (NASH), a condition with increasing prevalence and limited treatment options. The market for NASH therapeutics is projected to grow significantly, driven by rising obesity rates and increasing awareness of liver diseases. Zydus Therapeutics Inc. is positioned to capture market share if Saroglitazar demonstrates superior efficacy and safety compared to existing therapies. Competitive landscape includes other investigational drugs targeting NASH, necessitating robust clinical data to differentiate Saroglitazar. Diligence should focus on regulatory pathways and potential market access strategies, particularly in regions with high NASH prevalence.